Status
Conditions
About
The human immune response to bacterial blood stream infection (sepsis) and systemic viral infection are fairly well understood, but we lack details on the most early phases. Better knowledge of these events would be important for the prevention and treatment of severe bacterial or viral disease. From models of infection, we have data showing that bacteria replicate in a specific type of cells in the spleen from where the bacteria then seed to the blood to cause blood stream infection. In order to gain more relevant data for humans, we have developed a spleen perfusion model using pig organs. This model confirms our previous work and most importantly will now allow us to study these events in human organs.
In order to move novel treatment strategies into human trials, we propose to test early events during infection using human spleens and the cells and tissues derived thereof. This research is expected to provide data on the relevance of the early events in bacterial and viral disease, in particular on the role of immune cells. The research includes work with human cells and tissue obtained from human spleens. In these settings, we will test pharmacological prevention and treatment of severe bacterial or viral infection (sepsis). The expected outcome of this work on human organs and tissue is expected to provide evidence that allows to move new treatment options into clinical trial.
This study is a preclinical research project and does not involve any intervention on patients, but it involves human tissue. The source of the human splenic tissue for our research will be spleen tissue removed during radical surgery. The present application relates exclusively to the ethical approval for the use of spleen tissue removed during radical surgery and discarded. The utilisation of the spleen or splenic tissue for research purposes does not alter in any way the surgical procedures at any stage and importantly the research will involve only anonymity samples.
Full description
This is a preclinical research project and no patient intervention is planned. The project makes use of anonymised human tissue samples discarded during radical surgery. The spleen organ samples included in this project will be from patients undergoing elective surgery for a lesion in the pancreas in the HPB Unit of the Leicester General Hospital. The sample size of 100 (100 enrolled subjects for 42 spleens) has been determined by power calculations and is in line with the number of spleens actually removed by elective pancreas surgery over the past years. No change in the surgical procedure or recruiting results from this study and the use of the samples. All the experimental work carried out on the spleen samples will have no effect on the patient.
Experiments include ex vivo organ perfusion and infection with bacteria or viruses. Biopsies of the perfused 42 spleens are processed for in vitro tissue slice and macrophage cell culture. The resulting primary cell cultures and tissue slices will be stored frozen for future research. All in vitro studies on the 42 organs, and the tissues and cells derived from them, will evaluate the effect of therapeutic interventions (antibodies, receptor antagonists, antibiotics and other molecules) on the capacity of splenic cells to clear invasive bacteria or viruses. The experiments will be carried out each time a spleen sample will be available.
The detailed technical description of the experimental strategy including the strategy for storage and discarding of the human tissue will be as follows:
Sample transfer between units: The 42 planned organ perfusion will be performed at the laboratories of the HBP unit of the Leicester General Hospital. In selected cases organ perfusion might be performed at the Department of Genetics and Genome Biology of the University of Leicester. The relative HBA form has been obtained (Hazardous Biological Agents form GEN/45 Cell lines and primary human cell and tissue culture, date 02/10/2017). During and after perfusion, tissue samples for tissue slice culture and primary cell culture will be taken. These tissue samples will be transferred to the Department of Genetics and Genome Biology or Dept. of Infection and Immunity and Inflammation for the scheduled research work and will be stored there in accordance with regulations relative to the Human Tissue Act. Stored tissue slices and primary cell cultures may then be transferred for immunological studies to the University of Nottingham for experimental work detailed above for cell cultures. Conditions for handling, storage and transport are defined by the HBA form GEN45 and transfer will be regulated by an MTA.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
24 participants in 1 patient group
Loading...
Central trial contact
Marco Oggioni
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal